BCL6 and B-cell non-Hodgkin lymphoma: Further, inhibition of PRMT5 in B cell lymphoma resulted in markedly upregulation of BCL6 target genes, and concomitant inhibition of both BCL6 and PRMT5 exhibited synergistic killing of BCL6‐expressing lymphoma cells.